Angelika Bilger1, Dusan Milanovic2, Hannah Lorenz2, Oliver Oehlke2, Horst Urbach3, Marianne Schmucker2, Astrid Weyerbrock4, Carsten Nieder5, Anca-Ligia Grosu6. 1. Department of Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, Freiburg, Germany. Electronic address: angelika.bilger@uniklinik-freiburg.de. 2. Department of Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, Freiburg, Germany. 3. Department of Neuroradiology, University Medical Center Freiburg, Breisacher Straße 64, Freiburg, Germany. 4. Department of Neurosurgery, University Medical Center Freiburg, Breisacher Straße 64, Freiburg, Germany. 5. Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø 8092, Norway; Institute of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø 9037, Norway. 6. Department of Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, Freiburg, Germany; German Cancer Consortium (DKTK), Freiburg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abstract
OBJECTIVES: The goal of this study is to evaluate the role of stereotactic fractionated radiotherapy (SFRT) in patients with one to three brain metastases after surgical resection. METHODS AND MATERIALS: We performed a retrospective single-institutional study in patients undergoing SFRT of surgical cavity after resection of ≤3 brain metastases. 60 patients with newly diagnosed brain metastases treated with SFRT following resection were included. The total irradiation dose was 30 Gy (5 Gy/d, BED 45 Gy) after complete macroscopical resection and 35 Gy (5 Gy/d, BED 52.5 Gy) in patients with macroscopic residual tumour after surgery. Macroscopic residual tumour was defined as contrast enhancement next to the resection cavity on the postoperative T1-MRI. The gross tumour volume (GTV) encompassing the residual tumour was delineated on the T1-MRI, the clinical target volume (CTV) encompassed the surgical cavity plus 1mm and the planning target volume (PTV) the CTV plus 2mm. RESULTS: Eight of 60 patients had no imaging follow-up due to morbidity/mortality. Two of 52 (3.8%) patients experienced local failures only, 25 of 52 (48.1%) patients experienced distant intracranial failures only and 4 (7.7%) patients experienced both local and distant intracranial failures. In summary, there were 6 (11.5%) local failures and 29 (55.8%) distant failures. Age was significant for local control in the Cox regression test (p=0.046). Thirty-seven of 60 (61.7%) patients died during follow-up. Median follow-up was 8 months. Median overall survival was 15 months. Cox regression for survival was significant for KPS score ≤70% and size of PTV. No severe side effects were seen. Patients undergoing whole brain radiation therapy (WBRT) as salvage therapy in case of progression had no severe side effects either. CONCLUSION: In the light of encouraging local control rates, SFRT could be an alternative to WBRT after surgical resection of ≤3 brain metastases. Due to the high rate of distant intracranial failure regular follow-up with MRI is mandatory.
OBJECTIVES: The goal of this study is to evaluate the role of stereotactic fractionated radiotherapy (SFRT) in patients with one to three brain metastases after surgical resection. METHODS AND MATERIALS: We performed a retrospective single-institutional study in patients undergoing SFRT of surgical cavity after resection of ≤3 brain metastases. 60 patients with newly diagnosed brain metastases treated with SFRT following resection were included. The total irradiation dose was 30 Gy (5 Gy/d, BED 45 Gy) after complete macroscopical resection and 35 Gy (5 Gy/d, BED 52.5 Gy) in patients with macroscopic residual tumour after surgery. Macroscopic residual tumour was defined as contrast enhancement next to the resection cavity on the postoperative T1-MRI. The gross tumour volume (GTV) encompassing the residual tumour was delineated on the T1-MRI, the clinical target volume (CTV) encompassed the surgical cavity plus 1mm and the planning target volume (PTV) the CTV plus 2mm. RESULTS: Eight of 60 patients had no imaging follow-up due to morbidity/mortality. Two of 52 (3.8%) patients experienced local failures only, 25 of 52 (48.1%) patients experienced distant intracranial failures only and 4 (7.7%) patients experienced both local and distant intracranial failures. In summary, there were 6 (11.5%) local failures and 29 (55.8%) distant failures. Age was significant for local control in the Cox regression test (p=0.046). Thirty-seven of 60 (61.7%) patients died during follow-up. Median follow-up was 8 months. Median overall survival was 15 months. Cox regression for survival was significant for KPS score ≤70% and size of PTV. No severe side effects were seen. Patients undergoing whole brain radiation therapy (WBRT) as salvage therapy in case of progression had no severe side effects either. CONCLUSION: In the light of encouraging local control rates, SFRT could be an alternative to WBRT after surgical resection of ≤3 brain metastases. Due to the high rate of distant intracranial failure regular follow-up with MRI is mandatory.
Authors: Ahmad Walid Ayas; Stefan Grau; Karolina Jablonska; Daniel Ruess; Maximilian Ruge; Simone Marnitz; Roland Goldbrunner; Martin Kocher Journal: Strahlenther Onkol Date: 2018-09-14 Impact factor: 3.621
Authors: Sidyarth Garimall; Mihir Shanker; Erin Johns; Trevor Watkins; Sarah Olson; Michael Huo; Matthew C Foote; Mark B Pinkham Journal: J Neurooncol Date: 2020-01-06 Impact factor: 4.130
Authors: Christian D Diehl; Ehab Shiban; Christoph Straube; Jens Gempt; Jan J Wilkens; Markus Oechsner; Carmen Kessel; Claus Zimmer; Benedict Wiestler; Bernhard Meyer; Stephanie E Combs Journal: Cancer Commun (Lond) Date: 2019-11-09
Authors: Stephanie E Combs; Angelika Bilger; Christian Diehl; Eva Bretzinger; Hannah Lorenz; Oliver Oehlke; Hanno M Specht; Anna Kirstein; Anca-Ligia Grosu Journal: Cancer Med Date: 2018-04-25 Impact factor: 4.452
Authors: Angelika Bilger; Eva Bretzinger; Jamina Fennell; Carsten Nieder; Hannah Lorenz; Oliver Oehlke; Anca-Ligia Grosu; Hanno M Specht; Stephanie E Combs Journal: Cancer Med Date: 2018-05-09 Impact factor: 4.452